Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use


Por: Deleuran, M, Marcoux, D, De Bruin-Weller, MS, Irvine, AD, Baselga E, Ahn, K, Castro, AP, Bansal, A, Chao, JD, Bego-Le Bagousse, G and Rossi, AB

Publicada: 1 jul 2021
Resumen:


Filiaciones:
Deleuran, M:
 Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark

Marcoux, D:
 Univ Montreal, Div Dermatol, Dept Pediat, Montreal, PQ, Canada

 Ctr Hosp Univ St Justine, Montreal, PQ, Canada

De Bruin-Weller, MS:
 Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Natl Expertise Ctr Atop Dermatitis, Utrecht, Netherlands

Irvine, AD:
 Trinity Coll Dublin, Med Clin, Dublin, Ireland

 Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin, Ireland

Baselga E:
 Hosp Santa Creu & Sant Pau, Dept Dermatol, Barcelona, Spain

Ahn, K:
 Sungkyunkwan Univ, Dept Pediat, Samsung Med Ctr, Sch Med, Seoul, South Korea

Castro, AP:
 Univ Sao Paulo HC FMUSP, Inst Crianca, Hosp Clin, Allergy & Immunol Div,Pediat Dept,Fac Med, Sao Paulo, SP, Brazil

Bansal, A:
 Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

Chao, JD:
 Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

Bego-Le Bagousse, G:
 Sanofi, Chilly Mazarin, France

Rossi, AB:
 Sanofi Genzyme, Cambridge, MA USA
ISSN: 00015555





ACTA DERMATO-VENEREOLOGICA
Editorial
ACTA DERMATO-VENEREOLOGICA, TRADGARDSGATAN 14, UPPSALA SE-753 09, SWEDEN, Noruega
Tipo de documento: Editorial Material
Volumen: 101 Número:
Páginas:
WOS Id: 000685536600010
ID de PubMed: 34043020
imagen Green Submitted, gold

MÉTRICAS